Please upgrade your browser.
Patient Roger Willcocks will now receive a drug that was denied to him by the NHS.
The University of Michigan is presenting a symposium on the treatment options for patients and families dealing with Kidney Cancer
Sponsored by the UM Comprehensive Cancer Center, Department of Urology, Department of Internal Medicine Division of Hematology/Oncology.
A UT Southwestern Medical Center physician and other researchers have developed a unique statistical model that predicts the probability of a patient being cancer free 12 years after initial surgical treatment.
Combination failed to prevent disease progression or improve survival.
Tumor regressions were also observed in four additional patients, including two patients with melanoma, one patient with non-small cell lung cancer, and one with renal cell carcinoma.
In lab tests on human kidney cancer cells, their cancer-killing success rate was 90 percent.
Nexavar is currently approved in more than 40 countries for the treatment of patients with unresectable liver cancer and in more than 70 countries for the treatment of patients with advanced kidney cancer.
Preclinical rationale for combination targeted therapy in advanced clear cell renal cell carcinoma (RCC): Abrogation of rapamycin-mediated induction of AKT phosphorylation by perifosine.
Reaffirmed efficacy and safety of the drug as a treatment for advanced kidney cancer.
|Powered by NeonCRM|